PocDoc, a Cambridge, UK-based health-tech startup, raised £5M in Pre-A funding.
Backers included MMC Ventures, Molten VC and Simplyhealth Ventures, and KHP Ventures.
The company intends to use the funds to support its continued rapid growth, accelerated by its list of pharmacy, retail, and corporate partnerships, as well as its relationships with the NHS across the UK.
Founded by Steve Roest, Dr Vladimir Gubala and Dr Kiran Roest, PocDoc aims to make diagnostic testing for cardio, metabolic and renal disease as accessible as possible, to prevent these diseases from crippling health systems all over the world. It provides an app-based technology platform that combines proprietary, patented Microfluidic Assay (MFA) technology and cloud-based AI diagnostics to deliver end-to-end digital pathways for the assessment, diagnosis and treatment of major diseases.
Its patented MFA (microfluidic Assay) platform is a digital diagnostic test platform that can perform complex multi-marker interactions to a clinically valid standard.
The PocDocOS® platform provides the digital infrastructure for the future of point of care testing. Using machine learning, data and process integration, dynamic workflows, clinical teams and real-time alerting, it enables anyone with a smartphone or tablet to receive a full health assessment and critical follow on services, including speaking to a clinician, notifying GP, sending results to patient record and providing real-time treatment options.
PocDoc’s tests are available for free in regions where the company is already working with the NHS, in community pharmacies across the UK, via online retailers such as Pharmacy2U, and on PocDoc’s website.
FinSMEs
28/11/2024